Login to Pancreatic Cancer UK

Top US medical centres progress pancreatic cancer detection

Posted by: Research 2 August 2011

Research undertaken at the University of Vermont (UVM) and the Dartmouth-Hitchcock Medical Centre (DHMC) in New England has shown that using a tumour marker, serum CA 19-9, combined with an endoscopic ultrasound if the tumour marker is elevated, is more likely to detect stage 1 pancreatic cancer in a high-risk population than by using the standard means of detection. 

Alex Ford, CEO of Pancreatic Cancer UK comments: "Screening tools for pancreatic cancer amongst high risk groups are an important development.  We hope to see these in practice soon and potentially used as the basis to look for earlier diagnosis tests for the wider population as well."